Evommune, Inc. (EVMN)
NYQ · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Cannot generate headline: SEC filing content is missing
I apologize, but it looks like the actual text content of the SEC filing (the PDF data) was not included in your request. The input only provided the metadata tags (`<PDF>...</PDF>`) without the document itself. To maintain the detailed, expert analysis you expect, I need the full content of the AR
SEC filings
All filings →Insider trades
All insider trades →Evommune, Inc. has no reported insider trades in the last 90 days.